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Mesenchymal soluble factors confer imatinib drug 
resistance in chronic myelogenous leukemia cells
Ofer Regev1,2, Noa Kidan1,3, Meshel Nicola1,2, Hazem Khamisie1, Martin Ruthardt4, Jamal Mahajna1,2
Chronic myelogenous leukemia (CML) is characterized by a  t(9;22) 
chromosome translocation (Philadelphia chromosome-positive [Ph+]) 
that creates the BCR/ABL oncogene. This fusion protein displays con-
stitutive tyrosine kinase activity, leading to the induction of aberrant 
proliferation and neoplastic transformation [1]. The Ph+ chromosome 
is found in more than 95% of CML and in Ph+ acute lymphoblastic leu-
kemia. 
ABL tyrosine kinase inhibitors (AKIs) are utilized for the treatment of 
Ph+ leukemia; the initial response is beneficial [2–4] but unfortunately, 
the clinical efficacy of this treatment decreases steadily as the disease 
progresses [5]. CML blast crisis or Ph+ acute lymphoblastic leukemia pa-
tients only benefit from TKI treatment temporarily, if at all [6, 7]. 
Resistance to drug therapy in Ph+ leukemia is mediated by mutations 
within BCR/ABL or by BCR/ABL-independent mechanisms, such as tu-
mor microenvironment-mediated drug resistance [8]. The bone marrow 
(BM) plays a vital role in hematopoiesis, as well as in different aspects 
of disease progression in hematological malignancies [8, 9]. The BM 
microenvironment is also critical for long-term hematopoiesis, and for 
the maintenance and regulation of stem cells and their progeny [9]. It is 
a rich source of paracrine- and autocrine-derived factors which have also 
been implicated in drug resistance for both hematologic malignancies 
and solid tumors that metastasize to the BM [10–12]. Conditions within 
the BM niche, including soluble factors (SFs), interleukins (ILs), stromal 
cells, and extracellular components, contribute to reduced drug sensitiv-
ity of cancer cells [10, 13, 14], including drug resistance to multiple TKIs, 
such as imatinib, nilotinib, and dasatinib [15–19].
To explore the BCR/ABL-independent mechanisms underlying Ph+ leu-
kemia drug resistance, we investigated the ability of SFs collected from 
mesenchymal stem cells (MSCs) to confer drug resistance in CML cell 
lines in vitro. Exposure of CML cells to mesenchymal SFs conferred re-
sistance to imatinib, but not crizotinib, which was mediated in part by 
the Janus kinase/signal transducers and activators of transcription (JAK/
STAT) pathway. Inhibition of JAK2 by ruxolitinib restored sensitivity to 
imatinib in CML cells exposed to mesenchymal SFs. Moreover, the multi-
TKI crizotinib, which has been reported to also inhibit ABL tyrosine kinase 
Letter to the Editor
Hematology
Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
Arch Med Sci 1, December / 2020 267
activity, was also able to abrogate JAK2 activity, 
thereby overcoming SF-mediated drug resistance 
in Ph+ leukemia.
Blast crisis human chronic myelogenous leu-
kemia cell line K562 and megakaryocytic leuke-
mia cell line MEG-01 (American Type Culture Col-
lection (ATCC), VA, USA), and Ba/F3 JAK2 V617F 
cells expressing activated JAK2 and harboring the 
V617F mutation, have been described previously 
[20]. Cells were cultured in RPMI 1640 complete 
medium supplemented with 10% (w/v) fetal bo-
vine serum, 1% (w/v) L-glutamine, and penicillin/
streptomycin. The human and murine stromal 
cells HS-5 and MS-5, respectively (ATCC), were 
maintained under the same conditions. All cells 
were grown at 37°C in a humidified atmosphere 
with 5% CO2. 
HS-5 or MS-5 cells were grown in complete 
RPMI medium and CM were collected after 72 h. 
Contaminating cells were cleared by centrifuga-
tion at 1,000 rpm for 1 min; the collected super-
natant was used fresh in each experiment. 
Cells (2 × 105/well) were plated in six-well 
plates. After 24 h, cells were treated with the 
specified agents. Solvent-treated samples were 
incubated with 1% (w/v) dimethyl sulfoxide. Cells 
were collected 72 h later, stained with 0.4% (w/v) 
trypan blue solution (1 : 1, v/v), and counted using 
a hemacytometer [20].
Cytokine levels were measured in the CM of 
MS-5 cells using mouse cytokine array panel A 
(Proteome Profiler Array, R&D Systems, MN, USA). 
Briefly, CM were mixed with a  cocktail of bioti-
nylated detection antibodies. The CM–antibody 
mixture was then incubated with the mouse cy-
tokine array membrane. Following a wash to re-
move unbound material, streptavidin conjugated 
to horseradish peroxidase and chemiluminescent 
detection reagents were added sequentially. Data 
were visualized using X-ray film. Optical densities 
were determined using ImageJ software.
Clonogenicity assay was performed as previ-
ously described [21]. The plates were stained for 
4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide, and the dye was 
extracted with solubilization buffer (20% w/v so-
dium dodecyl sulfate (SDS), 50% w/v N,N-dimeth-
ylformamide, 25 mM HCl) for 24 h. Optical density 
was measured at 570 nm with a reference wave-
length of 630 nm.
Immunoblotting was performed as described 
previously [22]. Anti-pSTATs (phosphor-Stat an-
tibody sampler kit cat #9914), anti-JAK2 (cat 
#3230), anti-pJAK2 (Tyr 1007/1008)(cat #3776), 
anti-phosphor Abl (Tyr 245) (cat #2861) and an-
ti-cleaved PARP (cat #5625) antibodies were from 
Cell Signaling Technology (MA, USA). Anti-PARP 
(cat #SC-8007) antibodies were from Santa Cruz 
Biotechnology (CA, USA).
Figure 1. Mesenchymal stem cell (MSC) conditioned medium (CM) confers drug resistance to imatinib in CML cells. 
A – MEG-01 and K562 cells were exposed to increasing concentrations of CM (0, 6.25, 12.5, 25%) collected from 
MS-5 or HS-5, and viability of remaining cells after treatment with 1 μM imatinib for 72 h was determined. CM col-
lected from MS-5 or HS-5 supplied to MEG-01 and K562, respectively. B – MEG-01 and K562 cells were exposed to 
12.5% CM collected from MSC cells in the presence or absence of 1 μM imatinib for 72 h. Negative control – 12.5% 
RPMI medium +1% FCS. *,**Significantly different from untreated cells at p < 0.01 and 0.001, respectively. The ex-
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Student’s t-test was used for the statistical 
analyses, with the significance level set at p < 0.01 
or p < 0.001.
To address drug sensitivity of CML cell lines to 
AKIs in the presence of CM collected from MSC 
cells, we utilized human K562 [23] and MEG-01 
cells [24] as an in-vitro model of CML. We followed 
the effect of imatinib on proliferation and trigger-
ing of PARP cleavage as a marker of apoptosis in-
duction [25] in MEG-01 CML cells in the presence 
and absence of CM collected from MS-5 cells. Ex-
posure of MEG-01 cells to various concentrations 
of MS-5 CM (6.25–25%) resulted in increased cell 
survival in the presence of imatinib (Figure 1 A). In 
fact, as little as 3% MS-5 CM was sufficient to con-
fer partial drug resistance in MEG-01 cells treated 
with imatinib (data not shown). Next, we mea-
sured the effect of MS-5 CM on imatinib-induced 
growth inhibition using K562 and MEG-01 CML 
cells. MS-5 CM protected cells of both CML lines 
from imatinib-induced growth inhibition, albeit 
with varying potency. Overall, the magnitude of 
the drug resistance observed in MEG-01 cells was 
more than 2-fold greater than that in K562 cells 
(Figure  1 B). This suggested that murine SFs are 
active against human CML cells, although the basis 
for the different responses of K562 and MEG-01 
cells to MS-5 CM is unclear. Nevertheless, we chose 
to further focus on drug sensitivity of MEG-01 cells 
in response to exposure to MS-5 CM.
We asked whether CM collected from other cells 
might promote resistance to imatinib in MEG-01 
cells. CM collected from A2780 and B16-F10 cell lines 
were not efficient at conferring drug resistance to 
imatinib (Supplementary Figure S1 A). Additional 
data (Supplementary Figure S1 B) supported involve-
ment of SFs, but not microvessels, as mediators of 
drug resistance in CML exposed to MSC CM [26].
We recently demonstrated that crizotinib, an 
anaplastic lymphoma kinase (ALK)/ROS1 inhibi-
tor [27, 28], efficiently and selectively suppresses 
growth of Ph+ cells, and inhibits activity of native 
and T315I-mutated BCR/ABL [29, 30]. Here, we also 
explored the ability of CM collected from MSCs to 
induce drug resistance in MEG-01 cells exposed to 
crizotinib. Figure 2 shows that MS-5 CM conferred sig-
nificant drug resistance to imatinib in MEG-01 cells, 
but had a minimal protective effect in cells exposed 
to either ponatinib [31] or crizotinib (Figure 2 A). 
Next, we monitored the ability of MSC CM to in-
terfere with imatinib- and crizotinib-induced apop-
tosis of MEG-01 cells. Initially, MEG-01 cells were 
treated with crizotinib or imatinib for 24 h in the 
presence or absence of MS-5 CM. Exposure to ima-
tinib/crizotinib significantly increased the levels of 
cleaved PARP enzyme (Figure 2 B) [25]. Interestingly, 
the presence of MS-5 CM prevented PARP cleavage, 
again suggesting that it confers drug resistance to 
imatinib in MEG-01 cells (Figure 2 B). In contrast, 
exposure of MEG-01 cells to crizotinib resulted in 
significant cleavage of PARP, indicating induction of 
apoptosis (Figure 2 B). Next, we examined the ef-
fect of MS-5 CM on the activity of BCR/ABL in MEG-
01 cells exposed to imatinib or crizotinib. Data pre-
sented in Figures 2 C and D show that imatinib was 
active in inhibiting BCR/ABL auto-phosphorylation 
in the presence and absence of MS-5 CM. In addi-
tion, the high concentration of crizotinib was active 
at inhibiting BCR/ABL auto-phosphorylation, but 
showed only marginal activity at the low concen-
tration, in the presence and absence of MS-5 CM. 
Imatinib was active at inducing PARP cleavage in 
MEG-01 cells, and induction of PARP cleavage was 
largely reduced (by about 50%) in the presence of 
MS-5 CM. In contrast, crizotinib induction of PARP 
cleavage was not reduced, but rather enhanced in 
the presence of MS-5 CM. Thus, the apoptosis-in-
ducing activity of imatinib, but not of crizotinib, was 
reduced in the presence of MS-5 CM with no signif-
icant change in imatinib’s ability to inhibit BCR/ABL 
auto-phosphorylation. 
To identify potential SFs in the MS-5 CM that are 
involved in mediating drug resistance to imatinib, 
we monitored the levels of a  variety of SFs using 
a cytokine array assay kit. Figures 3 A and B shows 
a number of cytokines and ILs, in particular IL-3 and 
IL-17 (Figures 3 A, B), that were present at high levels 
in the MS-5 CM, whereas others, such as IL-1Ra and 
IL-12 p70, were present at low levels (Figures 3 A, B). 
We hypothesized that one or a few cytokines are in-
volved in mediating imatinib drug resistance in CML 
cells, and we selected IL-3 to further investigate this. 
Increasing concentrations of murine IL-3 conferred 
resistance to imatinib in MEG-01 cells in a dose-de-
pendent manner (Figure 3 C). 
JAK/STAT pathways are downstream regu-
lators of a  number of ILs, such as IL-6 and IL-3, 
which have also been implicated in drug resis-
tance in CML [15, 32, 33]. Moreover, emerging 
data also implicate the JAK/STAT pathway in 
BM-mediated drug resistance [15, 16, 19]. Thus, 
we investigated the involvement of the JAK/
STAT pathway in the observed imatinib resis-
tance in CML cells exposed to MS-5 CM. MEG-01 
cells were exposed to MSC CM and levels of vari-
ous phosphorylated STATs were monitored.
The levels of both pSTAT1 and pSTAT2 were un-
detectable in the MEG-01 cells, with no change 
after exposure to either MS-5 CM (Figure 4 A) or 
HS-5 CM (data not shown). Moreover, STAT6 and 
STAT3 were not phosphorylated in MEG-01 cells, 
and exposure to MS-5 or HS-5 CM significantly 
stimulated their phosphorylation levels. In con-
trast, STAT5, which is a direct downstream target 
of BCR/ABL [34–36], was significantly phosphory-
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lated in MEG-01 cells and the phosphorylation lev-
els were further increased upon exposure to both 
HS-5 and MS-5 CM (Figure 4 A). 
STATs are downstream transcription factors 
that are activated by JAKs in response to cytokine 
activation. Thus, we investigated the influence of 
JAK inhibitors on imatinib resistance mediated by 
MS-5 CM. Figure 4 B shows the viability of MEG-01 
cells exposed to MS-5 CM in the presence of ima-
tinib and the clinically approved JAK1/2 inhibitor 
Figure 2. Crizotinib overcomes mesenchymal stem cell (MSC) conditioned medium (CM)-mediated drug resistance. 
A – MEG-01 cells were exposed to 1 μM imatinib, ponatinib or crizotinib in the presence or absence of 12.5% 
HS-5 CM and the number of viable cells was counted after 72 h exposure. B – MEG-01 cells were exposed to 1 μM 
imatinib, ponatinib or crizotinib in the presence or absence of 12.5% MS-5 CM and the number of viable cells was 
counted after 72 h exposure. C – Immunoblot of MEG-01 cells exposed to 1 μM imatinib or crizotinib in the pres-
ence or absence of MS-5 CM. In addition, 1 mM imatinib or crizotinib was added to MEG-01 cells co-cultured with 
MS-5 cells. Filters were probed with anti-cleaved (c)-PARP antibody and a-tubulin was used as a loading control. 
D – Immunoblot of K562 cells exposed to 0.5 μM and 2 μM imatinib or crizotinib in the presence or absence of 
MS-5 CM. Filters were probed with anti-c-PARP antibody, anti-phospho Abl (Tyr 245) and anti-GAPDH was used as 
a loading control. E – Quantitation of experiment in D showing relative levels of cleaved PARP and phospho BCR/
ABL (relative to GAPDH). *Significantly different from untreated cells at p < 0.01. The experiment was repeated 
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ruxolitinib [37]. As expected, exposure of MEG-01 
cells to MS-5 CM conferred drug resistance to ima-
tinib, but not crizotinib. When ruxolitinib was add-
ed along with imatinib, MEG-01 sensitivity to the 
latter was partially restored (Figure 4 B), support-
ing the involvement of JAK1/2 in mediating the 
MSC CM-induced drug resistance. Further support 
for the ability of ruxolitinib to restore sensitivity 
to imatinib in the presence of MS-5 CM was pro-
vided by following the levels of cleaved PARP in 
MEG-01 cells treated with imatinib, crizotinib, rux-
olitinib, or imatinib + ruxolitinib in the presence 
and absence of MS-5 CM. Imatinib and crizotinib 
induced PARP cleavage in MEG-01 cells. However, 
no PARP cleavage was observed in MEG-01 cells 
treated with either imatinib or ruxolitinib alone in 
the presence of MS-5 CM (Figure 4 C). On the oth-
er hand, ruxolitinib + imatinib effectively caused 
significant PARP cleavage, indicating restoration 
of partial sensitivity of MEG-01 cells to imatinib in 
the presence of MS-5 CM (Figure 4 C).
Data presented in Figures 4 B and C show that 
inhibition of JAK1/2 (by ruxolitinib) can restore 
sensitivity to imatinib in CML cells exposed to 
MS-5 CM. We therefore speculated that crizo-
tinib’s ability to overcome mesenchymal SF-me-
diated drug resistance in CML might be related 
to JAK1/2 activity. To address this point, we uti-
lized a Ba/F3 model system in which cells become 
IL-3-independent upon introduction of activated 
JAK2 (JAK2 V617F) [20]. Use of this system al-
lowed us to monitor the direct effect of crizotinib 
on JAK2 activity. Initially, we monitored the effects 
of crizotinib and other relevant TKIs on the clo-
nogenicity of Ba/F3 JAK2 V617F cells. Figures 5 
A and B shows that the colony-forming ability of 
Ba/F3 JAK2 V617F cells was not affected by imati-
nib or other ABL inhibitors such as GNF-2 or GNF-
5 [38]. However, crizotinib inhibited clonogenicity 
of Ba/F3 JAK2 V617F cells with a potency compa-
rable to that of ruxolitinib. Interestingly, ponatinib 
was also a potent inhibitor of Ba/F3 JAK2 V617F 
clonogenicity. 
Next, we utilized the same cells to monitor direct 
inhibition of JAK2 auto-phosphorylation by crizo-
tinib. Ruxolitinib actively inhibited auto-phosphor-
ylation of JAK2 V617F, and crizotinib also exhibited 
strong inhibition of JAK2 auto-phosphorylation. 
In contrast, neither imatinib nor GNF-5 inhibited 
JAK2 auto-phosphorylation (Figures 5 C, D). 
CML-targeted therapy has proven to be very ef-
fective in managing the disease and has led to ex-
Figure 3. Identification of soluble factors (SFs) in MS-5 conditioned medium (CM) as potential mediators of ima-
tinib resistance in MEG-01 cells. CM was collected from MS-5 cells after 72 h of culture. A – Immunoblot test for 
relative expression levels of 40 factors in MS-5 CM was carried out according to the manufacturer’s instructions. 
B – Optic absorption was measured by TINA software and levels of soluble factors in MS-5 CM relative to RPMI are 
presented. C – Cell viability (number of remaining cells) of K562 cells treated with 1 μM imatinib and increasing 
concentrations of murine (m) IL-3 for 72 h was determined. *Significantly different from untreated cells at p < 0.01. 
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tended lifespans for many CML patients. However, 
about 30% of those patients fail to respond, re-
spond suboptimally, or experience disease relapse 
after treatment with CML-targeted therapy due, in 
part, to drug resistance [5, 39]. In general, Ph+ leu-
kemia resistance to drug therapy might be due to 
mutations in the cancer cells, including alterations 
in the BCR/ABL fusion gene, or associated with 
interactions between Ph+ leukemia cancer cells 
and the BM microenvironment, leading to tumor 
microenvironment-mediated drug resistance and 
consequently a  low level of residual disease and 
disease progression [8].
Intensive effort has been invested in develop-
ing strategies to address drug resistance in Ph+ 
leukemia by introducing new TKIs that are active 
against ABL1 mutations, including the gatekeeper 
T315I mutation [40]. Moreover, effort is still being 
made to target additional regulatory elements 
within the ABL1 kinase, such as the myristoyl-
binding pocket in the BCR/ABL protein [20, 41], or 
to use a drug combination [21, 42]. 
The BM microenvironment contributes signifi-
cantly to drug resistance in both hematologic ma-
lignancies and solid tumors that metastasize to 
the BM [10–12]. Conditions in the BM niche that 
contribute to reduced drug sensitivity might in-
clude SFs, stromal cells, and extracellular compo-
nents [10, 13, 14, 43]. Thus, modulation of signaling 
pathways involved in mediating the interaction, 
adhesion, or homing of hematopoietic cancer cells 
to BM stromal cells is expected to influence drug 
sensitivity in hematopoietic malignancies [13–16].
The BM microenvironment-mediated drug re-
sistance might be due to SFs or to cell adhesion to 
the microenvironment compartment. To address 
BM microenvironment-mediated drug resistance, 
we monitored the ability of CM collected from 
MSCs to affect the sensitivity of CML cells to ima-
tinib and crizotinib. We monitored the viability of 
CML cells as well as induction of PARP cleavage 
(Figures 1, 2), a marker of apoptosis induction [25]. 
MEG-01 cells were sensitive to imatinib and 
crizotinib as evidenced by inhibition of CML cell 
viability (Figures 1 A, B) and induction of PARP 
cleavage (Figures 2 B, C). However, CM collected 
from MSCs conferred resistance to imatinib, con-
sistent with previous observations [16]. Interest-
ingly, MEG-01 cells were more sensitive to MS-5 
CM than K562 cells. The presence of CM from 
MSCs reduced the sensitivity of the CML cells to 
imatinib-induced apoptosis, but not to crizotinib, 
suggesting that mesenchymal SFs can promote 
imatinib resistance with continued sensitivity to 
Figure 4. MS-5 conditioned medium (CM) stimulates JAK/STAT pathway in MEG-01 cells. A – MEG-01 cells exposed 
to 12.5% CM collected from MS-5 and HS-5 cultures were used to monitor levels of activated STATs by immunoblot-
ting. MEG-01 cells were seeded and exposed to 12.5% CM from MS-5/HS-5 cells for 2 h. Cells were collected, and the 
phosphorylation of STAT3/4/6 was monitored by immunoblotting. Tubulin was used as a loading control. B – MEG-01 
cell viability was monitored after exposure to 12.5% MS-5 CM in the presence of 1 μM imatinib, imatinib + ruxolitinib 
or crizotinib alone. Cell viability was monitored 72 h after treatment. C – Ability of different kinase inhibitors to in-
duce apoptosis in MEG-01 cells in the presence of MS-5 CM. MEG-01 cells were treated with 1 μM of the different Abl 
kinase inhibitors in the presence or absence of 12.5% CM for 24 h. The complete PARP protein (120 kDa) was used as 
a positive control. *,**Significantly different from untreated cells at p < 0.01 and 0.001, respectively. The experiment 
was repeated twice, with a comparable outcome
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the activity of crizotinib (Figure 2). We speculated 
that drug resistance stimulated by the CM is medi-
ated by SFs secreted by the MSCs. We identified 
a number of SFs that were present in significant 
amounts in the CM, such as IL-3, IL-1Ra, IL-17 and 
IL-12 p70, and speculated that one or a combina-
tion of these is responsible for mediating imatinib 
resistance in CML cells. Our speculation was sup-
ported by previous reports showing that IL-7 se-
creted by MSCs in the BM might protect leukemic 
cells from apoptosis induced by imatinib through 
the JAK/STAT-signaling pathway [44]. In addition, 
Jiang et al. [45] demonstrated autocrine produc-
tion and activity of IL-3 and granulocyte colony-
stimulating factor (G-CSF) in CML [45]. Moreover, 
culturing K562 cells with HS-5-derived CM signifi-
cantly inhibited apoptosis induced by imatinib via 
a STAT3-dependent mechanism [18], and imatinib 
sensitivity was restored by exposure to STAT3 in-
hibitor [46]. Our results are also corroborated by 
Zhang et al. [43], who found that CML stem cells 
demonstrate increased IL-1 receptor expression 
Figure 5. Crizotinib inhibits JAK2 activity. A – Ba/
F3 JAK2 V617F cells were used to monitor different 
kinase inhibitors’ effects on clonogenicity as de-
scribed in Material and methods. B – Areas of each 
sample were determined by monitoring absorbance 
using Image J and values obtained in samples treat-
ed with 0.1 μM and 1 μM kinase inhibitor were plot-
ted. C – Ba/F3 JAK2 V617F cells were exposed for 
1 h to different concentrations of imatinib, crizotinib 
(1, 3 and 10 μM) or GNF-5 (3 and 10 μM). Ruxolitinib 
at 1 μM was used as a positive control. Cells were 
collected and lysed and their proteins were sepa-
rated by SDS-PAGE. Levels of pJAK2 were monitored 
relative to JAK2 and a-tubulin was used as a load-
ing control. D – Levels of pJAK2 relative to a-tubulin. 
The experiment was repeated twice, with a compa-
rable outcome
GNF-5          3 10    _____________________________________________________________________
Crizotinib       1 3 10    _____________________________________________________________________
Imatinib    1 3 10    _____________________________________________________________________








































































Control 1 μM 3 μM 10 μM









 0.1 μM 1 μM 10 μM
Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
Arch Med Sci 1, December / 2020 273
and an enhanced signaling response; however, 
inhibition of IL-1 signaling when combined with 
TKIs enhanced anti-CML efficacy. In our study, we 
also monitored levels of activated STAT proteins 
and found that the presence of MSC CM results in 
activation of STAT3 and STAT6 (Figure 4). Increased 
activation of STAT3 has been associated with ma-
lignant cell transformation and drug-resistant tu-
mors [44, 46, 47]. Moreover, exposure of CML cells 
to MSC CM caused an increase in pSTAT3 and con-
sequently increased the expression of STAT3-regu-
lated genes such as Bcl-xl, Mcl-1, and survivin [46]. 
Thus, we argue that exposure to SFs that stimu-
late activation of STAT3 or STAT6 promotes the 
expression of a variety of antiapoptotic genes [48, 
49], and hence promotes drug resistance. 
JAK family kinases are the upstream activators 
of STAT proteins and also participate in mediating 
the function of a variety of cytokines [50]. Thus, 
we monitored the ability of the JAK1/2 inhibitor 
ruxolitinib [37] to abolish the drug resistance me-
diated by MSC CM. The presence of ruxolitinib 
restored partial imatinib sensitivity in CML cells 
exposed to MS-5 CM. Our results are consistent 
with data reported by Mencalha et al. [51] show-
ing that STAT3 inhibitor has an additive effect with 
imatinib in inducing apoptosis in CML cells, sug-
gesting a potential therapeutic value to combin-
ing these two drug regimens for the treatment of 
CML patients. Moreover, evidence for the poten-
tial of drug combinations in CML therapy was also 
provided by Ma et al. [52], who showed inhibition 
of growth and proliferation, cell-cycle blockade, 
and induction of apoptosis in K562 cells trans-
duced with STAT3 siRNA. Thus, the use of two 
components was recommended to overcome SF-
mediated drug resistance: one to inhibit BCR/ABL 
and the other to inhibit JAK1/2 activity. However, 
with the approval of multitarget kinase inhibitors, 
one might select those that are capable of inhibit-
ing both relevant targets. Previously, we demon-
strated that crizotinib efficiently inhibits kinase 
activity of native and T315I-mutated BCR/ABL [29]. 
In this study, we also found that crizotinib inhibits 
JAK2 activity. However, crizotinib activity against 
JAK1 remains to be determined. Crizotinib’s ability 
to inhibit JAK2 enables it to overcome JAK2-depen-
dent SF-mediated drug resistance. Similarly, pona-
tinib as a multi-kinase inhibitor was active in over-
coming SF-mediated drug resistance in MEG-01, 
in part by targeting JAK2 activity, probably indi-
rectly (Figure 5). The exact mechanism by which 
ponatinib inhibited clonogenicity of Ba/F3 JAK2 
V617F remains to be elucidated. 
In conclusion, the study showed that SFs secret-
ed from MSC, such IL-3 and IL-7, among others, are 
capable of activating the JAK/STAT pathway and 
consequently compromise the apoptosis-inducing 
activity of imatinib targeting CML cells. On the 
other hand, the multi-kinase inhibitor crizotinib, an 
FDA-approved drug for ALK-positive non-small cell 
lung carcinoma targeting ALK kinase, was found to 
inhibit BCR/ABL kinase activity and is also active 
in inhibiting JAK2. Exposure to crizotinib actively 
overcame drug resistance in CML mediated by SFs 
secreted from MSC. Our results raise the possibil-
ity of therapeutic use of crizotinib for CML patients 
who also require a JAK2 inhibitor to overcome BM 
microenvironment-mediated drug resistance. 
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